UY38964A - Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas - Google Patents
Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadasInfo
- Publication number
- UY38964A UY38964A UY0001038964A UY38964A UY38964A UY 38964 A UY38964 A UY 38964A UY 0001038964 A UY0001038964 A UY 0001038964A UY 38964 A UY38964 A UY 38964A UY 38964 A UY38964 A UY 38964A
- Authority
- UY
- Uruguay
- Prior art keywords
- oxadiazole
- agonists
- derivatives
- cross reference
- methods cross
- Prior art date
Links
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940061P | 2019-11-25 | 2019-11-25 | |
| US202063106293P | 2020-10-27 | 2020-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38964A true UY38964A (es) | 2021-06-30 |
Family
ID=73654860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038964A UY38964A (es) | 2019-11-25 | 2020-11-20 | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11427586B2 (https=) |
| EP (1) | EP4065228A1 (https=) |
| JP (1) | JP2023503320A (https=) |
| KR (1) | KR20220106778A (https=) |
| CN (1) | CN114746149A (https=) |
| AU (1) | AU2020394597B2 (https=) |
| BR (1) | BR112022009942A2 (https=) |
| CA (1) | CA3157657A1 (https=) |
| CL (1) | CL2022001323A1 (https=) |
| CO (1) | CO2022006645A2 (https=) |
| CR (1) | CR20220227A (https=) |
| DO (1) | DOP2022000107A (https=) |
| EC (1) | ECSP22040362A (https=) |
| IL (1) | IL291958A (https=) |
| JO (1) | JOP20220124A1 (https=) |
| MX (1) | MX2022006151A (https=) |
| PE (1) | PE20221785A1 (https=) |
| PH (1) | PH12022551248A1 (https=) |
| PY (1) | PY2077235A (https=) |
| TW (1) | TW202132289A (https=) |
| UY (1) | UY38964A (https=) |
| WO (1) | WO2021105857A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518128A (ja) * | 2021-05-20 | 2024-04-24 | ノバルティス アーゲー | ３－（（３－（４－（２－（イソブチルスルホニル）フェノキシ）－３－（トリフルオロメチル）フェニル）－１，２，４－オキサジアゾール－５－イル）メチル）－５，５－ジメチル－１－（２－モルホリノエチル）イミダゾリジン－２，４－ジオンの製剤 |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
| KR102882404B1 (ko) | 2022-10-28 | 2025-11-06 | (주)케이메디켐 | 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| US8729109B2 (en) * | 2011-09-08 | 2014-05-20 | Allergan, Inc. | 3-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulators |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| WO2015187840A2 (en) * | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
| JP2022514257A (ja) | 2018-12-13 | 2022-02-10 | アイノス，インコーポレイテッド | ドライアイ疾患の治療のための局所点眼製剤におけるｌｘｒアゴニスト |
-
2020
- 2020-11-20 PY PY202002077235A patent/PY2077235A/es unknown
- 2020-11-20 UY UY0001038964A patent/UY38964A/es not_active Application Discontinuation
- 2020-11-23 KR KR1020227020461A patent/KR20220106778A/ko not_active Ceased
- 2020-11-23 CN CN202080081467.7A patent/CN114746149A/zh active Pending
- 2020-11-23 BR BR112022009942A patent/BR112022009942A2/pt not_active Application Discontinuation
- 2020-11-23 JP JP2022529931A patent/JP2023503320A/ja active Pending
- 2020-11-23 EP EP20817082.9A patent/EP4065228A1/en not_active Withdrawn
- 2020-11-23 CR CR20220227A patent/CR20220227A/es unknown
- 2020-11-23 IL IL291958A patent/IL291958A/en unknown
- 2020-11-23 TW TW109140930A patent/TW202132289A/zh unknown
- 2020-11-23 PH PH1/2022/551248A patent/PH12022551248A1/en unknown
- 2020-11-23 AU AU2020394597A patent/AU2020394597B2/en not_active Expired - Fee Related
- 2020-11-23 US US17/101,510 patent/US11427586B2/en active Active
- 2020-11-23 CA CA3157657A patent/CA3157657A1/en active Pending
- 2020-11-23 WO PCT/IB2020/061053 patent/WO2021105857A1/en not_active Ceased
- 2020-11-23 PE PE2022000828A patent/PE20221785A1/es unknown
- 2020-11-23 MX MX2022006151A patent/MX2022006151A/es unknown
-
2022
- 2022-05-19 EC ECSENADI202240362A patent/ECSP22040362A/es unknown
- 2022-05-19 CO CONC2022/0006645A patent/CO2022006645A2/es unknown
- 2022-05-19 CL CL2022001323A patent/CL2022001323A1/es unknown
- 2022-05-20 DO DO2022000107A patent/DOP2022000107A/es unknown
- 2022-05-23 JO JOP/2022/0124A patent/JOP20220124A1/ar unknown
- 2022-06-06 US US17/805,487 patent/US20220340573A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022006151A (es) | 2022-08-02 |
| EP4065228A1 (en) | 2022-10-05 |
| US11427586B2 (en) | 2022-08-30 |
| JOP20220124A1 (ar) | 2022-05-23 |
| AU2020394597B2 (en) | 2024-03-14 |
| TW202132289A (zh) | 2021-09-01 |
| ECSP22040362A (es) | 2022-06-30 |
| PY2077235A (es) | 2022-10-31 |
| CO2022006645A2 (es) | 2022-05-31 |
| PH12022551248A1 (en) | 2023-09-11 |
| US20220340573A1 (en) | 2022-10-27 |
| CN114746149A (zh) | 2022-07-12 |
| IL291958A (en) | 2022-06-01 |
| JP2023503320A (ja) | 2023-01-27 |
| DOP2022000107A (es) | 2022-06-15 |
| AU2020394597A1 (en) | 2022-06-02 |
| CL2022001323A1 (es) | 2023-03-24 |
| CA3157657A1 (en) | 2021-06-03 |
| PE20221785A1 (es) | 2022-11-22 |
| WO2021105857A1 (en) | 2021-06-03 |
| BR112022009942A2 (pt) | 2022-08-09 |
| KR20220106778A (ko) | 2022-07-29 |
| CR20220227A (es) | 2022-06-15 |
| US20220064164A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| CR20210562A (es) | Agonistas de glp-1r y usos de los mismos | |
| CL2022001323A1 (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x | |
| CO2021015030A2 (es) | Inhibidores del inflamasoma nlrp3 | |
| CO2021000537A2 (es) | Inhibidores de inflamasoma nlrp3 | |
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
| AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
| CR20230256A (es) | Compuestos farmacéuticos | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| MX2021005240A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| MX2018012717A (es) | Administracion de una construccion biespecifica que se une a cd33 y cd3 para utilizar en un metodo paral el tratamiento de leucemia mieloide. | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| MX2023011377A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos. | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| CL2025001109A1 (es) | Compuestos derivados de pirazina-carboxamida. | |
| MX2021004342A (es) | Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20241206 |